- Home
- MNOV vs DXR Comparison
MNOV vs DXR Comparison
Compare MNOV & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | DXR |
|---|---|---|
| Founded | 2000 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.5M | 61.5M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNOV | DXR |
|---|---|---|
| Price | $1.53 | $12.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 103.8K | 4.3K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $257,917.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $33.97 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $6.55 |
| 52 Week High | $2.24 | $14.15 |
Technical Indicators
Market Signals| Indicator | MNOV | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 40.20 |
| Support Level | $1.48 | $12.11 |
| Resistance Level | $1.60 | $13.02 |
| Average True Range (ATR) | 0.06 | 0.47 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 60.53 | 6.75 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.